All About Merck's Molnupiravir Drug
Sam Fazeli, Director of Research, Bloomberg Intelligence
11-Oct-21 07:30
Embed Podcast
You can share this podcast by copying this HTML to your clipboard and pasting into your blog or web page.
Close
Last week, Health Minister Khairy Jamaludin said that the government would procure 150,000 treatment packages of a Covid-19 anti-viral drug produced by Merck called Molnupiravir. The drug is being described by many quarters as a gamechanger in the fight against Covid-19. Based on trials conducted so far, the medication was shown to reduce the risk of hospitalization or death by around 50% in patients with mild-to-moderate symptoms of the virus. We get the lowdown on Molnupiravir from Sam Fazeli, Director of Research at Bloomberg Intelligence.
Image credit: Quality Stock Arts / Shutterstock.com
Produced by: Shazana Mokhtar
Presented by: Wong Shou Ning, Philip See, Shazana Mokhtar
This and more than 60,000 other podcasts in your hand. Download the all new BFM mobile app.
Categories: Business Analysis, Trends and Forecasts, Markets, Politics, Social Issues, Health Policy, Diseases & Conditions, Mental Health, Healthy Living, Fitness, Medical Innovation and Technology, law & legal matters, Science, Investments
Tags: Merck, Covid-19, Medicine, Pandemic, Vaccinations, Global,